MRTX - Amgen and Mirati spike on FDA approval for KRAS inhibitor Lumakras in lung cancer

Amgen ([[AMGN]] +1.4%) and Mirati Therapeutics ([[MRTX]] +2.5%) are trading higher on the news of FDA approval for Lumakras (sotorasib) on priority review as a treatment for adults with non-small cell lung cancer ((NSCLC)).A once-daily oral small molecule, Lumakras is now indicated in a second line setting for NSCLC patients with a specific type of genetic mutation called KRAS G12C who have received at least one prior systemic therapy.Lumakras is considered the first approved targeted therapy for tumors with any KRAS mutation. In December, Amgen announced the FDA granted the Breakthrough Therapy for the treatment NSCLC patients with KRAS G12C mutation.Mirati Therapeutics is also advancing its KRASG12C inhibitor adagrasib (MRTX849) as monotherapy and in combination with other agents against cancer.

For further details see:

Amgen and Mirati spike on FDA approval for KRAS inhibitor Lumakras in lung cancer